Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Priscilla Hsue, MD
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05488431CT.gov Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cardiovascular Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bempedoic Acid (this asset) | Priscilla Hsue, MD | P2 | CCC · 53 |
| Aspirin | AstraZeneca | P4 | BBB |
| Liraglutide | University of Sao Paulo General Hospital | P4 | BBB |
| Atorvastatin | Duke University | P4 | BBB |
| Rosuvastatin | Nanjing First Hospital, Nanjing Medical University | P4 | BBB |
| Simvastatin | McMaster University | P4 | BBB |
| Ramifentanyl | Helse Fonna | P4 | BBB |
| Degarelix | Rabin Medical Center | P4 | BBB |
| Hydrochlorothiazide | Tehran University of Medical Sciences | P4 | BBB |
+42 more in the Cardiovascular Disorder cohort
Other indications for Bempedoic Acid
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Coronary Syndrome | — | P4 | BB · 65 |
| Inherited Lipid Metabolism Disorder | — | P2 | CCC · 53 |
| HIV Infectious Disease | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bempedoic Acid in Cardiovascular Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bempedoic-acid-cardiovascular-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →